Pura Vida Investments’s Metagenomi Therapeutics MGX Stock Holding History

Pura Vida Investments’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$354K	Hold	264,391	–	–	2.38%	10
2025 Q4	$428K	Hold	264,391	–	–	1.6%	10
2025 Q3	$627K	Sell	264,391 -687,743	-72%	-$1.4M	3.82%	7
2025 Q2	$391K	Buy	952,134 +687,743	+260%	+$1.08M	2.35%	8
2025 Q1	$360K	Hold	264,391	–	–	2.63%	7
2024 Q4	$954K	Sell	264,391 -6,227	-2%	-$15K	3.02%	14
2024 Q3	$587K	Hold	270,618	–	–	0.38%	37
2024 Q2	$1.04M	Sell	270,618 -190,665	-41%	-$1.31M	0.66%	41
2024 Q1	$4.87M	Buy	+461,283	New	+$5.3M	0.82%	23

Other funds holding MGX

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Pura Vida Investments's MGX Position: Q1 2026 in Review

Pura Vida Investments held its Metagenomi Therapeutics (MGX) position steady in Q1 2026 at 264,391 shares worth $354K. The position accounts for 2.38% of the portfolio, ranked #10.

Pura Vida Investments first reported a position in MGX in Q1 2024 and has held it in 9 quarters since. The position peaked at $4.87M in Q1 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

Pura Vida Investments held 264,391 shares of Metagenomi Therapeutics worth $354K as of Q1 2026.
Pura Vida Investments left its Metagenomi Therapeutics share count unchanged in Q1 2026.
Metagenomi Therapeutics made up 2.38% of Pura Vida Investments's portfolio in Q1 2026, its #10 holding.
Pura Vida Investments first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 9 quarters since.
Pura Vida Investments's Metagenomi Therapeutics position peaked at $4.87M in Q1 2024.
48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Pura Vida Investments's 13F filing for Q1 2026, filed 12 May 2026.